Xencor

XNCR Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$12.81

+2.23% today

52W: $6.92 – $18.69

52W Low: $6.92 Position: 50% 52W High: $18.69

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

7.48x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$939.5M

Market Capitalization

Revenue Growth

-46.5%

YoY Revenue Growth

Profit Margin

-73.2%

Net profit margin

ROE

-14.07%

Return on Equity

Beta

0.99

Market sensitivity

Short Interest

21.58%

% of float sold short

Avg. Volume

792,901

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

12 analysts

Avg. Price Target

$28.42

+121.83% upside

Target Range

$13.00 – $43.00

About the Company

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-c

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 260 Exchange: NGM